Mumbai-based Entod Pharmaceuticals has announced a significant global milestone in eye care therapeutics with the successful development of the world’s first losartan ophthalmic formulation for managing corneal wound scarring — a major cause of preventable vision loss worldwide.
Losartan, widely known as an oral antihypertensive agent, has recently shown strong anti-fibrotic and anti-scarring activity in corneal tissue, supported by published international research.
Entod’s R&D team has successfully repurposed and stabilised this molecule into a topical ophthalmic eye drop formulation at its DSIR approved R&D centre in Navi Mumbai. Developed using the company’s proprietary EyeBS™ advanced ionic buffer technology, this represents a global first in ophthalmic formulation science.
The company will soon commence the formal drug regulatory pathway in India, with clinical trials planned for early 2026 to evaluate safety, efficacy, and long-term outcomes.
The process includes obtaining approval from the Central Drugs Standard Control Organization (CDSCO) to initiate trials, followed by seeking Drug Controller General of India (DCGI) approval for commercialisation. The product will be marketed under the trademark OCUZART, available by prescription only.
Commenting on the medical significance, Dr Dr K V Satyamurthy, Senior Consultant, M M Joshi Eye Institute, Dharwad said, “Corneal scarring caused by trauma, infections, or post-surgical complications remains one of the leading causes of irreversible vision loss. Current treatments are limited, slow, and often invasive. India accounts for a large proportion of global cases due to high rates of ocular trauma, agricultural injuries, infectious keratitis, and delayed access to care. Entod’s losartan eye drops, once approved, could significantly reduce corneal fibrosis, enhance corneal clarity, and improve visual rehabilitation — marking a long-awaited pharmacological advance in this domain.”
